September 1997 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
Anti-IL-1 treatments might help with certain types of hair loss in people with high inflammation.
September 1997 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
Blocking IL-1 could help treat some hair loss conditions; alopecia affects liver detox systems; spironolactone is better than finasteride for female hair growth; focusing on the catagen hair phase could lead to new alopecia treatments.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
Dutasteride at 0.5 mg/day does not significantly alter allopregnanolone levels, but higher doses (2.5 mg/day) do. Dutasteride may also have anti-neuroinflammatory effects, but the impact on neurosteroids is still debated.
Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.
The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.
The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.